Prostamax is a synthetic peptide of four amino acids, a tetrapeptide [1][2]. It belongs to a family of short peptide bioregulators, small synthetic peptides that regulate gene expression in a target tissue [4][16]. Unlike the tissue extracts it was tested against, it is a single defined molecule made by chemical synthesis [1][2]. Its distinguishing claim is tissue specificity: the series includes peptides for liver, nerve and pineal tissue, while Prostamax was patented for the prostate, the organ below the bladder that produces seminal fluid [1][10].
Vladimir Khavinson, Vladimir Malinin and Evgeny Grigorev are named as inventors on the Russian patent for the peptide, held by the St. Petersburg Institute of Bioregulation and Gerontology; the application was filed on January 25, 2001, and published on January 10, 2002 [1][2]. The patent claims a peptide that regulates prostate function, normalizes metabolism and microcirculation in the gland, and has antioxidant activity [1]. Two 2004 papers report laboratory work in lymphocytes. Khavinson and colleagues tested Prostamax alongside four other short peptides in cells from donors aged 75 to 88 [4], and a separate study measured how the peptide changed chromatin packing in the same kind of cells [6].
Its research potential is concentrated in chromatin regulation and prostate tissue repair. Prostamax loosens heterochromatin in human lymphocytes outside the body [4][5] and reduces collagen deposition and prostate enlargement in two rat models [2][3]. Those results are early. As of October 2026, Drugs@FDA lists no approved application for Prostamax and ClinicalTrials.gov lists no registered study [15][14], and the human data come from cells studied outside the body [4][5][6]. The 2026 WADA and NCAA lists do not name it, so its competitive status depends on their class rules [12][13].
Key takeaways
- Prostamax is a synthetic four-amino-acid peptide, patented in Russia as a prostate regulator, with an application filed in 2001 and published in 2002 [1][2].
- In human lymphocytes outside the body it decondenses heterochromatin and shifts chromosome markers [4][5], and in rats it reduces prostate collagen and prostate enlargement in two small models [2][3].
- No human trial is registered [14], and as of October 2026 Drugs@FDA lists no approved application for it [15]. Neither the WADA nor the NCAA list names it, and both ban classes of related substances [12][13].
How it works
Chromatin loosening and gene expression
Prostamax appears to act on the way DNA is packaged, which would let genes that aging has switched off be read again. Chromatin is the complex of DNA and histone proteins that fills the nucleus; histones are the spool proteins the DNA wraps around. Tightly packed chromatin is heterochromatin, and the open, gene-reading form is euchromatin. Khavinson's group argues that short peptides of two to seven amino acids can enter the nucleus and interact with DNA, histones and the nucleosome, the basic DNA-histone unit [8].
The 2004 lymphocyte study is a direct test in human cells. White blood cells from donors aged 75 to 88 were exposed to the peptides in the laboratory, and all five tested activated ribosomal genes and decondensed densely packed chromatin [4]. Prostamax decondensed pericentromeric chromatin on chromosome 1, the tightly packed region around the centromere, the waist where the two chromatid arms join. Unlike Epitalon and Livagen, it did not change chromosome 9 in that experiment [4].
The 2012 follow-up measured chromosome markers in lymphocytes from donors aged 75 to 86 [5]. Prostamax raised sister chromatid exchanges to 12.0 per cell from 5.9 and silver-positive nucleolus organizer regions, the active ribosomal gene clusters, to 2.5 per cell from 0.95. It also reduced large pericentromeric heterochromatin blocks on chromosomes 1 and 9 [5]. The authors read the pattern as deheterochromatinization, the unrolling of condensed chromatin. A rise in sister chromatid exchanges is also a rearrangement signal, so the same number can be read as a caution flag; the abstract reports no separate damage assay [5].
The prostate as the target tissue
Prostamax was patented as a prostate regulator, and the animal work tests that claim in two different prostate models [1][2][3]. The 2006 study used organotypic culture, a method that keeps small pieces of tissue alive on a support so they retain their original mix of cell types [9]. Prostate explants from 3-week-old and 18-month-old rats were exposed to 0.05 nanograms per milliliter of Prostamax, and the peptide stimulated both age groups. The report gives the direction of the effect rather than a prostate-specific effect size.
The chronic prostatitis model used a silk suture through the ventral prostate to produce aseptic inflammation, meaning inflammation without a bacterial infection [2]. In a 60-rat study, 20 micrograms per kilogram intramuscularly for 15 days reduced collagen deposition more than 2.5-fold and kept epithelial area at the unoperated level, while swelling, vessel congestion and immune-cell infiltration were milder. Prostate weight and volume did not change significantly.
The benign prostatic hyperplasia model used sulpiride, a drug that raises prolactin, in a 40-rat study [3]. At 20 milligrams per kilogram for 60 days, prostate mass fell by 24 percent, weight coefficient by 25 percent and volume by 40 percent, and epithelial area fell by 22.4 percent. The two papers share authors and use doses 1,000-fold apart [2][3].
Cell entry and transport
A four-amino-acid peptide needs a route into the cell, and the transport papers test whether known carriers can supply one [10][11]. LAT1 and LAT2 are amino-acid transporters, membrane proteins that move neutral amino acids across. PEPT1 and PEPT2 are peptide transporters that normally carry di- and tripeptides, the two- and three-amino-acid products of protein digestion. Docking is a computer method that fits a molecule into a binding site and scores the fit; a more negative ICM score means a tighter predicted fit.
The 2022 review scored Prostamax at -13.58 for LAT1, a weak value, and noted that LAT1 is moderately expressed in the prostate but that the peptide does not show high binding to it [10]. The 2023 study found a strong PEPT1 signal, -33.42, second among 26 peptides, but its LAT2 score of -11.68 ranked last of the 26 and its LAT1 score of -22.79 ranked 22nd, even though the abstract lists Prostamax among the most effective ligands [11]. The authors still predict LAT2 binding, calling the LAT2 score higher than that of known inhibitors, although it is less negative than the three inhibitor scores listed. These are docking predictions, not transport measurements, and neither paper reports a laboratory uptake assay for the peptide [10][11].
What the mechanism does not explain
The working model places Prostamax inside the cell, where it can reach DNA and histones. No cell-surface receptor has been identified in the papers reviewed, and the transport scores do not settle how the peptide crosses the membrane [10][11]. The 2015 study shows that Prostamax changes DNA melting behavior, which makes direct contact plausible, though its docking model uses the single amino acids Glu and Lys rather than the intact tetrapeptide [7]. Khavinson's review work proposes that short peptides normalize tissue-specific protein synthesis and regulate genes for proliferation and differentiation, the process by which cells take on a specialized identity [16]. The 2021 review adds that short peptides can bind DNA and histones and alter methylation, a chemical tag that helps switch genes on or off [8].
What has been studied in humans
A ClinicalTrials.gov search on October 23, 2026 returned no study [14], and no PubMed-indexed trial appears in the literature reviewed. The human data come from lymphocytes studied outside the body, so they measure how cells respond to the peptide rather than what happens when a person receives it [4][5][6].
The 2004 study is the broadest human-cell experiment. It collected white blood cells from donors aged 75 to 88, exposed them to five short peptides, and measured ribosomal gene activity, chromatin melting and chromosome structure [4]. Prostamax activated ribosomal genes, decondensed chromosome 1 pericentromeric chromatin, and left chromosome 9 unchanged. The paper reports the five peptides as a group for most measures, so the Prostamax-specific result is the chromosome 1 finding.
The 2012 study focused on Prostamax alone. In lymphocytes from donors aged 75 to 86 it raised sister chromatid exchanges to 12.0 per cell from 5.9, raised silver-positive nucleolus organizer regions to 2.5 from 0.95, and reduced large pericentromeric heterochromatin blocks on chromosomes 1 and 9 [5]. The 2004 calorimetry study adds a physical measure: it found two DNA melting stages in human lymphocyte chromatin and reported that Prostamax shifted two endotherms to lower temperatures by 2.9 and 1.0 degrees Celsius, which the authors read as partial relaxation of the 30-nanometer fiber [6].
The gap matters for interpretation. An isolated lymphocyte sits outside the body's immune, hormonal and tissue context, and the donors were older adults, so the results describe an aged cell response rather than a clinical effect [4][5]. No human dose, safety or tolerability data appear in the papers reviewed [4][5][6].
Doses studied in human trials
As of October 2026, Prostamax remains without an FDA-approved application and without a registered clinical trial [15][14]. No published clinical trial appears in the indexed literature reviewed. The studies below are laboratory and animal studies.
20 micrograms per kilogram intramuscularly for 15 days, starting 30 days after surgery
60 male Wistar rats, 4 months old
20 milligrams per kilogram intramuscularly once daily for 60 days, alongside daily sulpiride 40 milligrams per kilogram
40 male Wistar rats, 10 months old
Lab and animal studies
Preclinical means work in cells, tissue or animals before a treatment reaches human testing. The Prostamax literature is small and comes from a handful of laboratories in Russia and Georgia. The two prostate studies are the strongest functional tests, and both are rat models [2][3].
The 2006 organotypic study tested prostate tissue directly. It kept prostate explants alive on a support and exposed them to 0.05 nanograms per milliliter of Prostamax. The abstract reports the direction of the effect, not a measure of peptide uptake [9]. Explants from both 3-week-old and 18-month-old rats responded, which the authors read as a repair signal that survives aging. The design tests a tissue fragment, not a whole animal.
The chronic prostatitis study tested the peptide against a mechanical injury. A silk suture through the ventral prostate produced swelling, vessel congestion, immune-cell infiltration, collagen deposition and epithelial atrophy over 45 days [2]. Prostamax given from day 30 to day 44 reduced the collagen area more than 2.5-fold and kept the epithelial area at the unoperated level. The paper also reports that the peptide did not change prostate weight or volume in this model, so the effect was on tissue composition rather than gland size.
The benign prostatic hyperplasia study used a hormonal model. Sulpiride raised prolactin and produced a prostate that was more than twice the mass of intact animals, with a 2.5-fold higher weight coefficient and a doubled volume [3]. Prostamax reversed part of that growth: mass fell by 24 percent, weight coefficient by 25 percent and volume by 40 percent relative to the sulpiride controls. The paper reports that a saw palmetto extract did not reduce prostate mass or volume, so the two agents are not interchangeable in this model.
The mechanistic work is thinner than the animal work. The 2015 DNA study shows that Prostamax changes the melting behavior of double-stranded DNA, but it models the separate amino acids rather than the folded peptide [7]. The 2022 review and 2023 docking paper draw on molecular modeling rather than new laboratory transport assays [10][11]. The two rat papers share authors, use doses 1,000-fold apart, and report no toxicology, pharmacokinetics or independent replication [2][3].
Research in detail
In vitro cytogenetic study of human lymphocytes exposed to five short peptides · Lymphocytes from donors aged 75 to 88 years
All five peptides activated ribosomal genes and decondensed chromatin; Prostamax decondensed chromosome 1 pericentromeric heterochromatin, while chromosome 9 changes appeared only with Epitalon and Livagen.
Evidence scope: Abstract reviewed; full text not read. Pooled results for five peptides, so the Prostamax-specific effect size is limited; cells were studied outside the body, no Prostamax dose is stated in the abstract, and no clinical outcome was measured.
In vitro cytogenetic study of sister chromatid exchanges, silver-stained nucleolus organizer regions and C-heterochromatin · Lymphocytes from donors aged 75 to 86 years
Prostamax raised sister chromatid exchanges to 12.0 per cell from 5.9, raised silver-positive nucleolus organizer regions to 2.5 per cell from 0.95, and reduced large pericentromeric heterochromatin segments on chromosomes 1 and 9.
Evidence scope: Abstract reviewed; full text not read. Cells were studied outside the body only; the abstract does not state the donor number or peptide concentration, and the authors read the exchange rise as chromatin opening without reporting a separate damage assay.
Differential scanning calorimetry of chromatin in human lymphocytes · Human lymphocytes
Prostamax shifted two DNA melting endotherms to lower temperatures by 2.9 and 1.0 degrees Celsius, which the authors read as partial relaxation of the 30-nanometer chromatin fiber.
Evidence scope: Abstract reviewed; full text not read. The donor number and peptide concentration are not stated, and calorimetry measures chromatin packing rather than gene activity.
Organotypic explant culture of prostate tissue from young and aged rats · Prostate explants from 3-week-old and 18-month-old rats
At 0.05 nanograms per milliliter, Prostamax stimulated prostate explants in both age groups.
Evidence scope: Abstract reviewed; full text not read. The paper reports the direction of the effect rather than an effect size, with no dose-response and no clinical endpoint.
Controlled rat study with a silk-suture model of chronic aseptic prostatitis and histological morphometry · 60 male Wistar rats, 4 months old
Prostamax reduced collagen deposition more than 2.5-fold compared with untreated controls, preserved epithelial area at the level of unoperated animals, and lessened swelling, vessel congestion and lymphoid infiltration; prostate weight and volume did not differ significantly from controls.
Evidence scope: Full text reviewed. Small groups, one laboratory, no blinding or randomization reported, and no clinical endpoint; the dose is 1,000-fold lower than the dose in the 2014 paper.
Controlled rat study with sulpiride-induced hyperprolactinemia and histological morphometry · 40 male Wistar rats, 10 months old
Prostamax reduced prostate mass by 24 percent, the weight coefficient by 25 percent and volume by 40 percent, and lowered the epithelial area by 22.4 percent; a saw palmetto extract lowered the epithelial area but did not reduce mass or volume.
Evidence scope: Full text reviewed. One laboratory, a drug-induced model that may not reflect spontaneous human disease, no blinding reported, and the 20 milligram per kilogram dose differs from the 20 microgram per kilogram dose in the 2013 paper.
In vitro DNA melting study with short peptides and a docking model of amino acid binding · Double-stranded DNA in solution
Prostamax changed the melting temperature and stability of the DNA double helix, consistent with an interaction between the peptide and DNA.
Evidence scope: Abstract reviewed; full text not read. Test-tube system; the abstract does not give the direction or size of the Prostamax effect, and the docking model uses single amino acids rather than the intact tetrapeptide.
Computational molecular docking of 26 ultrashort peptides against LAT1, LAT2, PEPT1 and PEPT2 · In silico transporter models
Prostamax scored -33.42 at PEPT1, second strongest of the 26 peptides; its LAT2 score of -11.68 ranked last and its LAT1 score of -22.79 ranked 22nd, though the authors predict LAT2 binding.
Evidence scope: Full text reviewed. Docking predicts binding, not transport or biological activity; no cells or animals were tested.
History and where it stands today
Prostamax moved from a Russian patent to a small laboratory literature on chromatin and rat prostate tissue, without a clinical trial.
- January 2002Russian patent RU 2177802 C1 publishes, claiming a four-amino-acid peptide that regulates prostate function, normalizes prostate metabolism and microcirculation, and has antioxidant activity [1].
- 2004Two papers report chromatin effects in human lymphocytes: one finds ribosomal gene activation across five short peptides and chromosome 1 decondensation with Prostamax, Epitalon and Livagen, and the other finds shifts in DNA melting consistent with a looser 30-nanometer fiber [4][6].
- 2006Prostate explants from young and aged rats respond to 0.05 nanograms per milliliter of Prostamax in organotypic culture, part of a panel testing four peptides on heart, lung, prostate and pancreas explants [9].
- 2012A Georgian team reports higher sister chromatid exchange and nucleolus organizer activity in aged lymphocytes, plus fewer large pericentromeric heterochromatin blocks on chromosomes 1 and 9 [5].
- 2013The Tomsk group reports that 20 micrograms per kilogram of Prostamax reduces collagen deposition and preserves epithelial area in a rat model of chronic aseptic prostatitis [2].
- 2014The same group reports that 20 milligrams per kilogram reduces prostate mass by 24 percent and volume by 40 percent in a sulpiride model of benign prostatic hyperplasia [3].
- 2022A computational review scores Prostamax as a weak LAT1 ligand and notes that prostate LAT1 expression does not explain its tissue specificity [10].
- 2023A follow-up docking study ranks Prostamax second of 26 peptides at PEPT1, 22nd at LAT1 and last at LAT2, while the authors still predict LAT2 binding [11].
- October 2026As of October 2026, Drugs@FDA lists no approved application for Prostamax and ClinicalTrials.gov lists no study [15][14]. WADA's 2026 list does not name it; S0 covers pharmacological substances not addressed by another section and with no current approval by any governmental regulatory health authority for human therapeutic use, and S2 has a similar-structure catch-all [12]. The NCAA 2026-27 list does not name it either; class 6 covers peptide hormones, growth factors and related substances, and the list adds a catch-all, as the NCAA page explains [13].
How it compares with related peptides
Testagen is another four-amino-acid peptide in the same series, and the transport review lists it as a regulator of the male reproductive system [10]. The docking work scores Testagen more strongly at LAT1 than Prostamax, -21.92 against -13.58. Both are studied for male reproductive tissue but differ in their docking profile [10]. Testagen has its own page for the reproductive-side research.
Livagen is another four-amino-acid peptide in the same series, and the 2004 lymphocyte study tested it alongside Prostamax [4]. Both peptides decondensed chromosome 1 pericentromeric chromatin, while Livagen also changed chromosome 9. The transport review lists Livagen as a hepatoprotector, a different tissue focus [10]. Livagen covers the chromatin and liver literature.
Epitalon is the peptide associated with pineal function in the same family, and the 2004 study found that it and Livagen, but not Prostamax, changed chromosome 9 [4]. The transport review lists Epitalon as a geroprotector and a regulator of pineal function [10]. Prostamax's tissue claim is the prostate, while Epitalon is studied as a broad aging peptide; Epitalon has the longer record.
Side effects and safety signals
The safety record is thin because no controlled study has given Prostamax to humans.
- No paper reviewed reports a human pharmacokinetic study, so how the peptide is absorbed, distributed, metabolized or excreted is unmeasured [4][5][6].
- The human-cell studies exposed lymphocytes in the laboratory, not living humans, and report no adverse events or tolerability data [4][5][6].
- The 2012 study reports a sister chromatid exchange rate of 12.0 per cell against 5.9 in intact cells; the authors read this as chromatin opening, and the abstract reports no separate DNA-damage assay [5].
- The two rat studies used 20 micrograms per kilogram and 20 milligrams per kilogram, a 1,000-fold difference, so the exposure range that has actually been tested is unclear [2][3].
- No formal toxicology, carcinogenicity, reproductive or immunogenicity studies of Prostamax appear in the literature reviewed [2][3][9].
- No pharmacopoeial monograph for Prostamax appears in the sources reviewed, and Drugs@FDA lists no approved application for the name, so identity and purity rest on supplier testing, which the COA library tracks [15].
- A theoretical concern is chromatin opening: a peptide that changes heterochromatin and chromosome structure could alter gene regulation in ways that are hard to predict, and the long-term consequence of the 2012 chromosome changes is unknown [5][7].
The future: what's next for Prostamax
A ClinicalTrials.gov search on October 23, 2026 returned no study of Prostamax [14], and Drugs@FDA lists no approved application for the name [15]. No sponsor has announced a first-in-human trial in the sources reviewed.
A clinical study would need to settle the dose question. The two rat papers used 20 micrograms per kilogram and 20 milligrams per kilogram, and neither reports plasma levels [2][3]. A pharmacokinetic study in an animal model, followed by a dose-ranging toxicology study, would establish what exposure the efficacy models actually tested. Identity and purity methods would need to be fixed first, the kind of testing the COA verification guide describes.
The biological questions are equally open. The transport scores point to PEPT1, and the authors predict LAT2 binding, but neither paper reports a laboratory assay of whether those carriers move Prostamax [10][11]. The chromatin work points to DNA and histones, but the 2015 study models single amino acids rather than the intact peptide [7].
- Which molecule does Prostamax bind inside the cell, and is DNA the direct target or a downstream stop?
- Does the chromatin opening seen in lymphocytes outside the body happen in living prostate tissue, and does it change a coherent set of genes?
- Which exposure is real, given the 1,000-fold difference between the two rat studies?
- Can an independent laboratory reproduce the rat prostate results, and do they translate to humans?
- Is the effect tissue-specific, or would a four-amino-acid peptide loosen chromatin in many tissues?